Cadila Healthcare Q4 PAT spurts 73% to Rs 679 cr

On a consolidated basis, the drug maker's net profit surged 73.25% to Rs 679 crore on 2.52% increase in total revenue from operations to Rs 3,846.70 crore in Q4 March 2021 over Q4 March 2020.
Profit before exceptional items, tax and share of profit of joint ventures rose 5% year-on-year to Rs 603.10 crore in Q4 FY21. EBIDTA grew by 8% to Rs 855 crore during the fourth quarter from the same quarter, last year.
During the financial year, Cadila Healthcare's net profit spurted 81.33% to Rs 2,133.60 crore on 5.95% rise in total revenue from operations to Rs 15,102.20 crore in FY 2021 over FY 2020. The EBIDTA for the year stood at Rs 3,341 crore, registering 20% growth over the previous year.

Related Keywords

United States ,India , ,Drug Administration ,Cadila Healthcare ,Abbreviated New Drug Applications ,United States Food ,Capital Market ,Finance Commission Of India ,Generic Pharmaceuticals ,Harmaceutical ,Covid Infection ,Healthcare Therapies ,Major ,Antibodies ,Nited States Food And Drug Administration ,Biological Therapy ,Europe ,ஒன்றுபட்டது மாநிலங்களில் ,இந்தியா ,காடிலா சுகாதாரம் ,ஒன்றுபட்டது மாநிலங்களில் உணவு ,மூலதனம் சந்தை ,நிதி தரகு ஆஃப் இந்தியா ,ந்திய ,